NCT07013279View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Glabellar Lines
Interventions
BIOLOGICAL

DWP712 inj.

Clostridium botulinum Toxin

BIOLOGICAL

Botox® 100 Units

Clostridium botulinum Toxin

Trial Locations (1)

Unknown

Chung-Ang University Hosptial, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY